Pancreatic Neuroendocrine Tumor

• FDA approval · 2015-04-24
  FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)

  FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals.

• FDA approval · 2014-12-19
  FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)

  The FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals.

• FDA approval · 2013-08-30
  FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)

  The FDA overview notes a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals. The submission status is …

• FDA approval · 2012-08-29
  FDA Approved: AFINITOR DISPERZ — Original Application (Novartis Pharmaceuticals Corporation)

  FDA approves AFINITOR DISPERZ (everolimus) under an Original Application for a dispersible tablet formulation.

• FDA approval · 2012-06-28
  FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Meitheal Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for octreotide acetate from Meitheal Pharmaceuticals, authorizing a generic version of the drug.…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2009-03-03
  FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  FDA approved a supplemental application for octreotide acetate submitted by Hikma Pharmaceuticals USA Inc., under the ANDA pathway.